MX359119B - Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas. - Google Patents
Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas.Info
- Publication number
- MX359119B MX359119B MX2013014461A MX2013014461A MX359119B MX 359119 B MX359119 B MX 359119B MX 2013014461 A MX2013014461 A MX 2013014461A MX 2013014461 A MX2013014461 A MX 2013014461A MX 359119 B MX359119 B MX 359119B
- Authority
- MX
- Mexico
- Prior art keywords
- sustained release
- release formulations
- eye
- delivery
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una formulación farmacéutica líquida para inyección en el ojo para la liberación sostenida de una proteína terapéutica, caracterizada porque comprende: un excipiente no polimérico biocompatible, biodegradable, líquido, en donde dicho excipiente es benzoato de bencilo; y un polímero de poli(d, l-láctico-co-glicólido) (PLGA) biodegradable, biocompatible que tiene una relación de láctido:glicólido de 50:50, intervalo de peso molecular 7,000-17,000 y un grupo terminal alquiléster; en donde la relación en % de peso del excipiente no polimérico: polímero es 90:10 a 99:1, incluso; en donde durante y después de inyectar de 5 µl a 100 µl de la formulación, usando una aguja de calibre 25, 27, 28, 30 o menor, la formulación mantiene su integridad monolítica y estado líquido; y en donde la formulación libera la proteína terapéutica de la formulación por un período de por lo menos 14 días.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161495672P | 2011-06-10 | 2011-06-10 | |
PCT/US2012/041950 WO2013036309A2 (en) | 2011-06-10 | 2012-06-11 | Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014461A MX2013014461A (es) | 2014-05-14 |
MX359119B true MX359119B (es) | 2018-09-14 |
Family
ID=47832748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014461A MX359119B (es) | 2011-06-10 | 2012-06-11 | Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas. |
Country Status (21)
Country | Link |
---|---|
US (1) | US9814773B2 (es) |
EP (1) | EP2717914B1 (es) |
JP (1) | JP6339011B2 (es) |
KR (1) | KR20140060274A (es) |
CN (1) | CN103945865B (es) |
AU (1) | AU2012304909B2 (es) |
BR (1) | BR112013031685B1 (es) |
CA (1) | CA2838289C (es) |
CY (1) | CY1122771T1 (es) |
DK (1) | DK2717914T3 (es) |
ES (1) | ES2761340T3 (es) |
HR (1) | HRP20192276T1 (es) |
HU (1) | HUE047737T2 (es) |
IN (1) | IN2013MN02384A (es) |
LT (1) | LT2717914T (es) |
MX (1) | MX359119B (es) |
PL (1) | PL2717914T3 (es) |
PT (1) | PT2717914T (es) |
RS (1) | RS60051B1 (es) |
SI (1) | SI2717914T1 (es) |
WO (1) | WO2013036309A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2913336C (en) * | 2013-05-24 | 2020-12-15 | Icon Bioscience, Inc. | Use of sustained release dexamethasone in post-cataract surgery inflammation |
SG11201608835VA (en) * | 2014-05-08 | 2016-11-29 | Panoptes Pharma Ges M B H | Compounds for treating ophthalmic diseases and disorders |
EP3272362B1 (en) * | 2015-03-18 | 2023-12-13 | Santen Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition |
CA2991015A1 (en) * | 2015-07-01 | 2017-01-05 | Santen Pharmaceutical Co., Ltd. | Depot preparation containing citric acid ester |
EA036951B1 (ru) * | 2015-08-03 | 2021-01-19 | Толмар Интернэшнл Лимитед | Жидкая полимерная система доставки для длительного введения лекарственных средств |
HUE063850T2 (hu) | 2015-09-21 | 2024-02-28 | Teva Pharmaceuticals Int Gmbh | Hosszan tartó felszabadulású olanzapin készítmények |
CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
KR101957599B1 (ko) | 2017-10-23 | 2019-03-13 | 김상현 | 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지 |
EP3749386A4 (en) | 2018-02-09 | 2021-10-27 | Icon Bioscience, Inc. | SYSTEMS, KITS AND METHODS FOR LOADING AND DISPENSING A SMALL VOLUME DOSE FROM A SYRINGE |
JP2021523223A (ja) | 2018-05-01 | 2021-09-02 | チビ,インコーポレイティド | 眼への薬物の非侵襲的な持続型送達のための液体デポー |
AU2019262061A1 (en) | 2018-05-01 | 2020-11-26 | Chibi, Inc. | Eye drop formulation and method for sustained delivery of medicament to the retina |
EP4153214A4 (en) * | 2020-05-22 | 2024-06-26 | Trustees of Boston University | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASE |
US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
KR20240117521A (ko) | 2021-07-06 | 2024-08-01 | 마크 하슬레톤 | 세로토닌 재흡수 억제제 금단 증후군의 치료 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658432B1 (fr) * | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
NZ523385A (en) * | 2000-06-28 | 2005-09-30 | Atul J | Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin |
US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
AR039729A1 (es) * | 2002-06-25 | 2005-03-09 | Alza Corp | Formulaciones de deposito de corta duracion |
US20050079202A1 (en) * | 2003-05-30 | 2005-04-14 | Guohua Chen | Implantable elastomeric depot compositions and uses thereof |
US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
MX366832B (es) * | 2004-10-01 | 2019-07-24 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
AU2005294382A1 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
US8039010B2 (en) * | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
CA2792484C (en) * | 2009-03-12 | 2017-10-31 | Delpor, Inc. | Implantable device for long-term delivery of drugs |
ES2672806T3 (es) * | 2009-07-03 | 2018-06-18 | Armbruster Biotechnology Gmbh | Injerto óseo y material biocompuesto |
-
2012
- 2012-06-11 LT LTEP12829655.5T patent/LT2717914T/lt unknown
- 2012-06-11 ES ES12829655T patent/ES2761340T3/es active Active
- 2012-06-11 AU AU2012304909A patent/AU2012304909B2/en active Active
- 2012-06-11 BR BR112013031685-3A patent/BR112013031685B1/pt active IP Right Grant
- 2012-06-11 CA CA2838289A patent/CA2838289C/en active Active
- 2012-06-11 PL PL12829655T patent/PL2717914T3/pl unknown
- 2012-06-11 DK DK12829655.5T patent/DK2717914T3/da active
- 2012-06-11 MX MX2013014461A patent/MX359119B/es active IP Right Grant
- 2012-06-11 IN IN2384MUN2013 patent/IN2013MN02384A/en unknown
- 2012-06-11 JP JP2014514933A patent/JP6339011B2/ja active Active
- 2012-06-11 RS RS20191574A patent/RS60051B1/sr unknown
- 2012-06-11 KR KR1020147000443A patent/KR20140060274A/ko not_active Application Discontinuation
- 2012-06-11 CN CN201280028816.4A patent/CN103945865B/zh active Active
- 2012-06-11 HU HUE12829655A patent/HUE047737T2/hu unknown
- 2012-06-11 EP EP12829655.5A patent/EP2717914B1/en active Active
- 2012-06-11 SI SI201231706T patent/SI2717914T1/sl unknown
- 2012-06-11 PT PT128296555T patent/PT2717914T/pt unknown
- 2012-06-11 WO PCT/US2012/041950 patent/WO2013036309A2/en active Application Filing
- 2012-06-11 US US14/124,631 patent/US9814773B2/en active Active
-
2019
- 2019-12-17 HR HRP20192276TT patent/HRP20192276T1/hr unknown
-
2020
- 2020-01-17 CY CY20201100042T patent/CY1122771T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013036309A3 (en) | 2013-05-10 |
KR20140060274A (ko) | 2014-05-19 |
US20140140992A1 (en) | 2014-05-22 |
EP2717914A4 (en) | 2015-05-13 |
CA2838289A1 (en) | 2013-03-14 |
AU2012304909A1 (en) | 2013-12-19 |
MX2013014461A (es) | 2014-05-14 |
NZ619707A (en) | 2015-01-30 |
BR112013031685B1 (pt) | 2021-04-06 |
US9814773B2 (en) | 2017-11-14 |
JP6339011B2 (ja) | 2018-06-06 |
BR112013031685A2 (pt) | 2017-02-07 |
IN2013MN02384A (es) | 2015-06-12 |
EP2717914B1 (en) | 2019-10-30 |
PL2717914T3 (pl) | 2020-05-18 |
LT2717914T (lt) | 2020-03-25 |
JP2014516087A (ja) | 2014-07-07 |
WO2013036309A2 (en) | 2013-03-14 |
HUE047737T2 (hu) | 2020-05-28 |
CY1122771T1 (el) | 2021-05-05 |
ES2761340T3 (es) | 2020-05-19 |
HRP20192276T1 (hr) | 2020-05-15 |
DK2717914T3 (da) | 2020-01-20 |
CA2838289C (en) | 2019-09-10 |
EP2717914A2 (en) | 2014-04-16 |
SI2717914T1 (sl) | 2020-07-31 |
RS60051B1 (sr) | 2020-04-30 |
AU2012304909B2 (en) | 2017-06-08 |
CN103945865B (zh) | 2016-10-26 |
PT2717914T (pt) | 2019-12-18 |
CN103945865A (zh) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013014461A (es) | Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas. | |
WO2016042163A3 (en) | Ophthalmic drug compositions | |
PH12017500023A1 (en) | Targeted conjugates and particles and formulations thereof | |
NZ704011A (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
MX2013003892A (es) | Composicion farmaceutica liquida para el suministro de ingredientes activos. | |
WO2012054500A3 (en) | Compositions for drug administration | |
MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
MX2018001499A (es) | Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos. | |
MX364396B (es) | Poli(beta-amino esteres) modificados para suministro de farmaco. | |
SG194175A1 (en) | Polymer conjugated prostaglandin analogues | |
UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
MX2015008286A (es) | Composiciones multipolimericas para liberación transdermica de farmaco. | |
MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
WO2011112996A3 (en) | Injectable drug delivery system | |
MX2014011537A (es) | Formulaciones parenterales para la administracion de antibioticos macrolidos. | |
WO2014104974A3 (en) | Self-assembling ultrashort peptides modified with bioactive agents by click chemistry | |
MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
IN2014DN08870A (es) | ||
MX2022003939A (es) | Composicion farmaceutica de estabilidad mejorada. | |
WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
MX341642B (es) | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. | |
BR112015011294A8 (pt) | nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas | |
MX2017005163A (es) | Composiciones de liberación prolongada de onapristona y métodos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |